Ranibizumab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Ranibizumab" in English language version.

refsWebsite

Global rank English rank

33web.archive.org

1^st place

28nih.gov

4^th place

14europa.eu

68^th place

117^th place

13doi.org

2^nd place

3tga.gov.au

3,984^th place

2,622^nd place

3fda.gov

447^th place

338^th place

2gene.com

low place

2harvard.edu

18^th place

17^th place

2medscape.com

719^th place

636^th place

1hres.ca

low place

1hpfb-dgpsa.ca

low place

1healio.com

low place

1wne.edu

low place

1pharmabiz.com

low place

1globenewswire.com

2,614^th place

1,549^th place

1pharmacytimes.com

low place

1sandoz.com

low place

1marketscreener.com

7,438^th place

5,529^th place

1washingtonpost.com

34^th place

27^th place

1nytimes.com

7^th place

1semanticscholar.org

11^th place

8^th place

doi.org

Heidary F, Hitam WH, Ngah NF, George TM, Hashim H, Shatriah I (March 2011). "Intravitreal Ranibizumab for Choroidal Neovascularization in Best's Vitelliform Macular Dystrophy in a 6-Year-Old Boy". Journal of Pediatric Ophthalmology and Strabismus. 48 Online (6): e19 – e22. doi:10.3928/01913913-20110308-02. PMID 21417187. Archived from the original on 1 October 2021. Retrieved 1 October 2021.
Formoso G, Marata AM, Magrini N, Bero L (September 2014). Tovey D (ed.). "A clearer view of evidence in treating macular degeneration: off-label policies and independent research". The Cochrane Database of Systematic Reviews. 9 (9): ED000090. doi:10.1002/14651858.ED000090. PMC 10845851. PMID 25228121.
Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS (August 2014). "Anti-vascular endothelial growth factor for neovascular age-related macular degeneration". The Cochrane Database of Systematic Reviews. 8 (8): CD005139. doi:10.1002/14651858.CD005139.pub3. PMC 4270425. PMID 25170575.
Sarwar S, Clearfield E, Soliman MK, Sadiq MA, Baldwin AJ, Hanout M, et al. (February 2016). "Aflibercept for neovascular age-related macular degeneration". The Cochrane Database of Systematic Reviews. 2016 (2): CD011346. doi:10.1002/14651858.CD011346.pub2. PMC 5030844. PMID 26857947.
Virgili G, Curran K, Lucenteforte E, Peto T, Parravano M, et al. (Cochrane Eyes and Vision Group) (June 2023). "Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis". The Cochrane Database of Systematic Reviews. 2023 (6): CD007419. doi:10.1002/14651858.CD007419.pub7. PMC 10294542. PMID 38275741.
Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U, et al. (September 2014). Moja L (ed.). "Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration". The Cochrane Database of Systematic Reviews. 9 (9): CD011230. doi:10.1002/14651858.CD011230.pub2. PMC 4262120. PMID 25220133.
Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M, et al. (2012). "A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard". PLOS ONE. 7 (8): e42701. Bibcode:2012PLoSO...742701S. doi:10.1371/journal.pone.0042701. PMC 3411814. PMID 22880086.
Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M, et al. (2012). "A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard". PLOS ONE. 7 (8): e42701. Bibcode:2012PLoSO...742701S. doi:10.1371/journal.pone.0042701. PMC 3411814. PMID 22880086.
Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (May 2011). "Ranibizumab and bevacizumab for neovascular age-related macular degeneration". The New England Journal of Medicine. 364 (20): 1897–1908. doi:10.1056/NEJMoa1102673. PMC 3157322. PMID 21526923.
Hutton D, Newman-Casey PA, Tavag M, Zacks D, Stein J (June 2014). "Switching to less expensive blindness drug could save medicare part B $18 billion over a ten-year period". Health Affairs. 33 (6): 931–939. doi:10.1377/hlthaff.2013.0832. PMC 4137040. PMID 24889941.
Subramanian ML, Abedi G, Ness S, Ahmed E, Fenberg M, Daly MK, et al. (November 2010). "Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial". Eye. 24 (11): 1708–1715. doi:10.1038/eye.2010.147. PMID 20885427.
Jiang S, Park C, Barner JC (June 2014). "Ranibizumab for age-related macular degeneration: a meta-analysis of dose effects and comparison with no anti-VEGF treatment and bevacizumab". Journal of Clinical Pharmacy and Therapeutics. 39 (3): 234–239. doi:10.1111/jcpt.12146. PMID 24635444. S2CID 23979022.
Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, et al. (IVAN study investigators) (October 2013). "Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial". Lancet. 382 (9900): 1258–1267. doi:10.1016/S0140-6736(13)61501-9. PMID 23870813.

europa.eu

ema.europa.eu

"Byooviz EPAR". European Medicines Agency. 23 June 2021. Archived from the original on 10 September 2021. Retrieved 9 September 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Epruvy EPAR". European Medicines Agency. 25 July 2024. Retrieved 27 July 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Ranivisio EPAR". European Medicines Agency (EMA). 20 June 2022. Archived from the original on 6 October 2022. Retrieved 6 October 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Rimmyrah EPAR". European Medicines Agency (EMA). 5 January 2024. Retrieved 7 September 2024.
"Ximluci EPAR". European Medicines Agency. 14 September 2022. Archived from the original on 13 March 2023. Retrieved 3 March 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Lucentis EPAR". European Medicines Agency. 17 September 2018. Archived from the original on 10 September 2021. Retrieved 9 September 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Ranivisio: Pending EC decision". European Medicines Agency. 22 June 2022. Archived from the original on 26 June 2022. Retrieved 26 June 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Ximluci: Pending EC decision". European Medicines Agency (EMA). 15 September 2022. Archived from the original on 19 September 2022. Retrieved 18 September 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Rimmyrah: Pending EC decision". European Medicines Agency. 10 November 2023. Archived from the original on 13 November 2023. Retrieved 5 December 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

ec.europa.eu

"Epruvy PI". Union Register of medicinal products. 24 September 2024. Retrieved 4 March 2025.
"Byooviz Product information". Union Register of medicinal products. Archived from the original on 3 March 2023. Retrieved 3 March 2023.
"Ranivisio Product information". Union Register of medicinal products. Archived from the original on 3 March 2023. Retrieved 3 March 2023.
"Ximluci Product information". Union Register of medicinal products. Archived from the original on 17 November 2022. Retrieved 3 March 2023.
"Rimmyrah PI". Union Register of medicinal products. 9 January 2024. Retrieved 7 September 2024.

fda.gov

accessdata.fda.gov

"Drug Approval Package: Lucentis (Ranibizumab) NDA #125156". U.S. Food and Drug Administration (FDA). 26 September 2006. Archived from the original on 2 August 2022. Retrieved 2 August 2022.
"Susvimo: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 3 August 2022. Retrieved 2 August 2022.

fda.gov

"FDA Approves First Biosimilar to Treat Macular Degeneration Disease and Other Eye Conditions". U.S. Food and Drug Administration (FDA) (Press release). 20 September 2021. Archived from the original on 20 September 2021. Retrieved 20 September 2021. This article incorporates text from this source, which is in the public domain.

gene.com

"Lucentis Fact Sheet". Genentech. Archived from the original on 28 October 2012. Retrieved 28 October 2012.
"Susvimo Prescribing Information" (PDF). Genentech, Inc. Archived (PDF) from the original on 13 July 2024. Retrieved 23 July 2024.

globenewswire.com

"FDA Approves Coherus' Cimerli (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis for All Five Indications, with 12 Months of Interchangeability Exclusivity" (Press release). Coherus BioSciences. 2 August 2022. Archived from the original on 3 August 2022. Retrieved 2 August 2022 – via GlobeNewswire News Room.

harvard.edu

ui.adsabs.harvard.edu

Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M, et al. (2012). "A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard". PLOS ONE. 7 (8): e42701. Bibcode:2012PLoSO...742701S. doi:10.1371/journal.pone.0042701. PMC 3411814. PMID 22880086.
Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M, et al. (2012). "A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard". PLOS ONE. 7 (8): e42701. Bibcode:2012PLoSO...742701S. doi:10.1371/journal.pone.0042701. PMC 3411814. PMID 22880086.

healio.com

journals.healio.com

Heidary F, Hitam WH, Ngah NF, George TM, Hashim H, Shatriah I (March 2011). "Intravitreal Ranibizumab for Choroidal Neovascularization in Best's Vitelliform Macular Dystrophy in a 6-Year-Old Boy". Journal of Pediatric Ophthalmology and Strabismus. 48 Online (6): e19 – e22. doi:10.3928/01913913-20110308-02. PMID 21417187. Archived from the original on 1 October 2021. Retrieved 1 October 2021.

hpfb-dgpsa.ca

dhpp.hpfb-dgpsa.ca

"Summary Basis of Decision for Ranopto". Drug and Health Products Portal. 1 September 2012. Retrieved 23 July 2024.

hres.ca

hpr-rps.hres.ca

"Summary Basis of Decision - Byooviz". Health Canada. 12 August 2022. Archived from the original on 29 September 2022. Retrieved 29 September 2022.

marketscreener.com

"Sandoz: acquisition of ophthalmology biosimilar". MarketScreener. 22 January 2024. Archived from the original on 10 March 2024. Retrieved 22 January 2024.

medscape.com

reference.medscape.com

"ranibizumab". medscape. Archived from the original on 30 March 2015. Retrieved 24 March 2015.

medscape.com

Henderson D (17 June 2014). "Switch From Lucentis to Avastin Could Save Medicare $18B". Medscape. Archived from the original on 29 August 2021.

nih.gov

pubmed.ncbi.nlm.nih.gov

Heidary F, Hitam WH, Ngah NF, George TM, Hashim H, Shatriah I (March 2011). "Intravitreal Ranibizumab for Choroidal Neovascularization in Best's Vitelliform Macular Dystrophy in a 6-Year-Old Boy". Journal of Pediatric Ophthalmology and Strabismus. 48 Online (6): e19 – e22. doi:10.3928/01913913-20110308-02. PMID 21417187. Archived from the original on 1 October 2021. Retrieved 1 October 2021.
Ramin S, Soheilian M, Habibi G, Ghazavi R, Gharebaghi R, Heidary F (2015). "Age-Related Macular Degeneration: A Scientometric Analysis". Medical Hypothesis, Discovery & Innovation in Ophthalmology. 4 (2): 39–49. PMC 4458325. PMID 26060829.
Formoso G, Marata AM, Magrini N, Bero L (September 2014). Tovey D (ed.). "A clearer view of evidence in treating macular degeneration: off-label policies and independent research". The Cochrane Database of Systematic Reviews. 9 (9): ED000090. doi:10.1002/14651858.ED000090. PMC 10845851. PMID 25228121.
Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS (August 2014). "Anti-vascular endothelial growth factor for neovascular age-related macular degeneration". The Cochrane Database of Systematic Reviews. 8 (8): CD005139. doi:10.1002/14651858.CD005139.pub3. PMC 4270425. PMID 25170575.
Sarwar S, Clearfield E, Soliman MK, Sadiq MA, Baldwin AJ, Hanout M, et al. (February 2016). "Aflibercept for neovascular age-related macular degeneration". The Cochrane Database of Systematic Reviews. 2016 (2): CD011346. doi:10.1002/14651858.CD011346.pub2. PMC 5030844. PMID 26857947.
Virgili G, Curran K, Lucenteforte E, Peto T, Parravano M, et al. (Cochrane Eyes and Vision Group) (June 2023). "Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis". The Cochrane Database of Systematic Reviews. 2023 (6): CD007419. doi:10.1002/14651858.CD007419.pub7. PMC 10294542. PMID 38275741.
Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U, et al. (September 2014). Moja L (ed.). "Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration". The Cochrane Database of Systematic Reviews. 9 (9): CD011230. doi:10.1002/14651858.CD011230.pub2. PMC 4262120. PMID 25220133.
Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M, et al. (2012). "A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard". PLOS ONE. 7 (8): e42701. Bibcode:2012PLoSO...742701S. doi:10.1371/journal.pone.0042701. PMC 3411814. PMID 22880086.
Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M, et al. (2012). "A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard". PLOS ONE. 7 (8): e42701. Bibcode:2012PLoSO...742701S. doi:10.1371/journal.pone.0042701. PMC 3411814. PMID 22880086.
Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (May 2011). "Ranibizumab and bevacizumab for neovascular age-related macular degeneration". The New England Journal of Medicine. 364 (20): 1897–1908. doi:10.1056/NEJMoa1102673. PMC 3157322. PMID 21526923.
Hutton D, Newman-Casey PA, Tavag M, Zacks D, Stein J (June 2014). "Switching to less expensive blindness drug could save medicare part B $18 billion over a ten-year period". Health Affairs. 33 (6): 931–939. doi:10.1377/hlthaff.2013.0832. PMC 4137040. PMID 24889941.
Subramanian ML, Abedi G, Ness S, Ahmed E, Fenberg M, Daly MK, et al. (November 2010). "Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial". Eye. 24 (11): 1708–1715. doi:10.1038/eye.2010.147. PMID 20885427.
Jiang S, Park C, Barner JC (June 2014). "Ranibizumab for age-related macular degeneration: a meta-analysis of dose effects and comparison with no anti-VEGF treatment and bevacizumab". Journal of Clinical Pharmacy and Therapeutics. 39 (3): 234–239. doi:10.1111/jcpt.12146. PMID 24635444. S2CID 23979022.
Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, et al. (IVAN study investigators) (October 2013). "Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial". Lancet. 382 (9900): 1258–1267. doi:10.1016/S0140-6736(13)61501-9. PMID 23870813.

ncbi.nlm.nih.gov

Ramin S, Soheilian M, Habibi G, Ghazavi R, Gharebaghi R, Heidary F (2015). "Age-Related Macular Degeneration: A Scientometric Analysis". Medical Hypothesis, Discovery & Innovation in Ophthalmology. 4 (2): 39–49. PMC 4458325. PMID 26060829.
Formoso G, Marata AM, Magrini N, Bero L (September 2014). Tovey D (ed.). "A clearer view of evidence in treating macular degeneration: off-label policies and independent research". The Cochrane Database of Systematic Reviews. 9 (9): ED000090. doi:10.1002/14651858.ED000090. PMC 10845851. PMID 25228121.
Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS (August 2014). "Anti-vascular endothelial growth factor for neovascular age-related macular degeneration". The Cochrane Database of Systematic Reviews. 8 (8): CD005139. doi:10.1002/14651858.CD005139.pub3. PMC 4270425. PMID 25170575.
Sarwar S, Clearfield E, Soliman MK, Sadiq MA, Baldwin AJ, Hanout M, et al. (February 2016). "Aflibercept for neovascular age-related macular degeneration". The Cochrane Database of Systematic Reviews. 2016 (2): CD011346. doi:10.1002/14651858.CD011346.pub2. PMC 5030844. PMID 26857947.
Virgili G, Curran K, Lucenteforte E, Peto T, Parravano M, et al. (Cochrane Eyes and Vision Group) (June 2023). "Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis". The Cochrane Database of Systematic Reviews. 2023 (6): CD007419. doi:10.1002/14651858.CD007419.pub7. PMC 10294542. PMID 38275741.
Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U, et al. (September 2014). Moja L (ed.). "Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration". The Cochrane Database of Systematic Reviews. 9 (9): CD011230. doi:10.1002/14651858.CD011230.pub2. PMC 4262120. PMID 25220133.
Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M, et al. (2012). "A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard". PLOS ONE. 7 (8): e42701. Bibcode:2012PLoSO...742701S. doi:10.1371/journal.pone.0042701. PMC 3411814. PMID 22880086.
Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M, et al. (2012). "A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard". PLOS ONE. 7 (8): e42701. Bibcode:2012PLoSO...742701S. doi:10.1371/journal.pone.0042701. PMC 3411814. PMID 22880086.
Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (May 2011). "Ranibizumab and bevacizumab for neovascular age-related macular degeneration". The New England Journal of Medicine. 364 (20): 1897–1908. doi:10.1056/NEJMoa1102673. PMC 3157322. PMID 21526923.
Hutton D, Newman-Casey PA, Tavag M, Zacks D, Stein J (June 2014). "Switching to less expensive blindness drug could save medicare part B $18 billion over a ten-year period". Health Affairs. 33 (6): 931–939. doi:10.1377/hlthaff.2013.0832. PMC 4137040. PMID 24889941.

dailymed.nlm.nih.gov

"Byooviz Nuna- ranibizumab injection, solution". DailyMed. 27 April 2022. Archived from the original on 3 August 2022. Retrieved 2 August 2022.
"Cimerli- ranibizumab-eqrn injection, solution". DailyMed. 19 October 2022. Archived from the original on 21 January 2023. Retrieved 21 January 2023.
"Susvimo- ranibizumab injection, solution". DailyMed. Archived from the original on 19 December 2021. Retrieved 19 December 2021.
"Lucentis- ranibizumab injection, solution". DailyMed. Archived from the original on 21 September 2021. Retrieved 20 September 2021.

nytimes.com

Pollack A (3 November 2010). "Genentech Offers Secret Rebates for Eye Drug". The New York Times. Archived from the original on 9 November 2020. Retrieved 25 February 2017.

pharmabiz.com

"Lupin receives CDSCO committee approval for marketing ranibizumab". www.pharmabiz.com. Archived from the original on 24 November 2021. Retrieved 24 November 2021.

pharmacytimes.com

"FDA Approves Ranibizumab-eqrn Biosimilar, Interchangeable with Lucentis". Pharmacy Times. 3 August 2022. Archived from the original on 19 February 2023. Retrieved 22 January 2024.

sandoz.com

"Sandoz announces agreement to acquire Cimerli business from Coherus, strengthening position in US market". Sandoz (Press release). Archived from the original on 29 January 2024. Retrieved 22 January 2024.

semanticscholar.org

api.semanticscholar.org

Jiang S, Park C, Barner JC (June 2014). "Ranibizumab for age-related macular degeneration: a meta-analysis of dose effects and comparison with no anti-VEGF treatment and bevacizumab". Journal of Clinical Pharmacy and Therapeutics. 39 (3): 234–239. doi:10.1111/jcpt.12146. PMID 24635444. S2CID 23979022.

tga.gov.au

"Raniviz APMDS". Therapeutic Goods Administration (TGA). 8 January 2024. Archived from the original on 8 February 2024. Retrieved 7 March 2024.
"AusPAR: Ranibizumab". Therapeutic Goods Administration (TGA). 9 December 2014. Archived from the original on 21 September 2021. Retrieved 20 September 2021.
"Byooviz APMDS". Therapeutic Goods Administration (TGA). 6 September 2022. Retrieved 7 March 2024.

washingtonpost.com

Whoriskey P, Keating D (7 December 2013). "An effective eye drug is available for $50. But many doctors choose a $2,000 alternative". The Washington Post. Archived from the original on 26 January 2021. Retrieved 10 September 2017.

web.archive.org

"Byooviz Nuna- ranibizumab injection, solution". DailyMed. 27 April 2022. Archived from the original on 3 August 2022. Retrieved 2 August 2022.
"Byooviz EPAR". European Medicines Agency. 23 June 2021. Archived from the original on 10 September 2021. Retrieved 9 September 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Cimerli- ranibizumab-eqrn injection, solution". DailyMed. 19 October 2022. Archived from the original on 21 January 2023. Retrieved 21 January 2023.
"Ranivisio EPAR". European Medicines Agency (EMA). 20 June 2022. Archived from the original on 6 October 2022. Retrieved 6 October 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Raniviz APMDS". Therapeutic Goods Administration (TGA). 8 January 2024. Archived from the original on 8 February 2024. Retrieved 7 March 2024.
"Susvimo- ranibizumab injection, solution". DailyMed. Archived from the original on 19 December 2021. Retrieved 19 December 2021.
"Ximluci EPAR". European Medicines Agency. 14 September 2022. Archived from the original on 13 March 2023. Retrieved 3 March 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"AusPAR: Ranibizumab". Therapeutic Goods Administration (TGA). 9 December 2014. Archived from the original on 21 September 2021. Retrieved 20 September 2021.
"Summary Basis of Decision - Byooviz". Health Canada. 12 August 2022. Archived from the original on 29 September 2022. Retrieved 29 September 2022.
"Lucentis- ranibizumab injection, solution". DailyMed. Archived from the original on 21 September 2021. Retrieved 20 September 2021.
"Lucentis EPAR". European Medicines Agency. 17 September 2018. Archived from the original on 10 September 2021. Retrieved 9 September 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
Heidary F, Hitam WH, Ngah NF, George TM, Hashim H, Shatriah I (March 2011). "Intravitreal Ranibizumab for Choroidal Neovascularization in Best's Vitelliform Macular Dystrophy in a 6-Year-Old Boy". Journal of Pediatric Ophthalmology and Strabismus. 48 Online (6): e19 – e22. doi:10.3928/01913913-20110308-02. PMID 21417187. Archived from the original on 1 October 2021. Retrieved 1 October 2021.
"Lucentis Fact Sheet". Genentech. Archived from the original on 28 October 2012. Retrieved 28 October 2012.
"Drug Approval Package: Lucentis (Ranibizumab) NDA #125156". U.S. Food and Drug Administration (FDA). 26 September 2006. Archived from the original on 2 August 2022. Retrieved 2 August 2022.
"FDA Approves First Biosimilar to Treat Macular Degeneration Disease and Other Eye Conditions". U.S. Food and Drug Administration (FDA) (Press release). 20 September 2021. Archived from the original on 20 September 2021. Retrieved 20 September 2021. This article incorporates text from this source, which is in the public domain.
"Susvimo Prescribing Information" (PDF). Genentech, Inc. Archived (PDF) from the original on 13 July 2024. Retrieved 23 July 2024.
"Susvimo: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 3 August 2022. Retrieved 2 August 2022.
Ranibizumab Archived 29 August 2021 at the Wayback Machine, Lexi-Drugs. Ranibizumab. Lexi-Comp, Inc.; 2007.
"ranibizumab". medscape. Archived from the original on 30 March 2015. Retrieved 24 March 2015.
"Byooviz Product information". Union Register of medicinal products. Archived from the original on 3 March 2023. Retrieved 3 March 2023.
"Lupin receives CDSCO committee approval for marketing ranibizumab". www.pharmabiz.com. Archived from the original on 24 November 2021. Retrieved 24 November 2021.
"Ranivisio: Pending EC decision". European Medicines Agency. 22 June 2022. Archived from the original on 26 June 2022. Retrieved 26 June 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Ranivisio Product information". Union Register of medicinal products. Archived from the original on 3 March 2023. Retrieved 3 March 2023.
"FDA Approves Coherus' Cimerli (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis for All Five Indications, with 12 Months of Interchangeability Exclusivity" (Press release). Coherus BioSciences. 2 August 2022. Archived from the original on 3 August 2022. Retrieved 2 August 2022 – via GlobeNewswire News Room.
"Ximluci: Pending EC decision". European Medicines Agency (EMA). 15 September 2022. Archived from the original on 19 September 2022. Retrieved 18 September 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Ximluci Product information". Union Register of medicinal products. Archived from the original on 17 November 2022. Retrieved 3 March 2023.
"Rimmyrah: Pending EC decision". European Medicines Agency. 10 November 2023. Archived from the original on 13 November 2023. Retrieved 5 December 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"FDA Approves Ranibizumab-eqrn Biosimilar, Interchangeable with Lucentis". Pharmacy Times. 3 August 2022. Archived from the original on 19 February 2023. Retrieved 22 January 2024.
"Sandoz announces agreement to acquire Cimerli business from Coherus, strengthening position in US market". Sandoz (Press release). Archived from the original on 29 January 2024. Retrieved 22 January 2024.
"Sandoz: acquisition of ophthalmology biosimilar". MarketScreener. 22 January 2024. Archived from the original on 10 March 2024. Retrieved 22 January 2024.
Whoriskey P, Keating D (7 December 2013). "An effective eye drug is available for $50. But many doctors choose a $2,000 alternative". The Washington Post. Archived from the original on 26 January 2021. Retrieved 10 September 2017.
Henderson D (17 June 2014). "Switch From Lucentis to Avastin Could Save Medicare $18B". Medscape. Archived from the original on 29 August 2021.
Pollack A (3 November 2010). "Genentech Offers Secret Rebates for Eye Drug". The New York Times. Archived from the original on 9 November 2020. Retrieved 25 February 2017.

wne.edu

0-online.lexi.com.wildpac.wne.edu

Ranibizumab Archived 29 August 2021 at the Wayback Machine, Lexi-Drugs. Ranibizumab. Lexi-Comp, Inc.; 2007.